New drugs for the treatment of coronary artery syndromes: otamixaban and ticagrelor

Affiliations

¹ Queensland University of Technology, School of Life Sciences, Faculty of Science and Technology, GPO Box 2343, Queensland 4001, Brisbane, Australia. sheila.doggrell@qut.edu.au

Comment

Sheila A Doggrell. Expert Opin Pharmacother. 2010 Feb.

. 2010 Feb;11(2):325-9.

doi: 10.1517/14656560903473173.

¹ Queensland University of Technology, School of Life Sciences, Faculty of Science and Technology, GPO Box 2343, Queensland 4001, Brisbane, Australia. sheila.doggrell@qut.edu.au

No abstract available

Comment on

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.
Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E. Sabatine MS, et al. Lancet. 2009 Sep 5;374(9692):787-95. doi: 10.1016/S0140-6736(09)61454-9. Epub 2009 Aug 28. Lancet. 2009. PMID: 19717184 Clinical Trial.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators; Freij A, Thorsén M. Wallentin L, et al. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30. N Engl J Med. 2009. PMID: 19717846 Clinical Trial.